1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals Holding Co., Ltd

2607.HK
Shanghai Pharmaceuticals Holding Co., LtdHK flagHong Kong Stock Exchange
11.75
HKD
+0.02
- -
68.16BMarket Cap
Shanghai Pharmaceuticals Holding Co., Ltd
2607.HK
(Hong Kong Stock Exchange)

Recent

price

11.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19.43
22.68
25.32
29.09
34.36
39.24
44.91
48.66
56.16
65.83
67.44
75.85
66.49
70.46
74.37
76.29
57.52
Revenue per Share
0.73
0.84
0.76
0.82
0.96
1.07
1.19
1.31
1.37
1.44
1.58
1.79
1.61
1.02
1.23
1.54
1.37
Basic EPS, GAAP
0.82
0.56
0.16
0.03
0.02
-0.14
-0.06
0.24
0.42
1.15
1.35
0.33
0.59
0.61
0.93
1.03
-0.48
Free Cash Flow per Basic Share
0.29
0.32
0.33
0.39
0.47
0.51
0.54
0.65
0.83
0.91
0.85
0.94
0.89
1.08
0.97
0.75
0.42
Dividend per Share
2.76
3.26
3.5
4.06
4.72
5.45
6.26
7.17
7.83
8.76
9.8
11.05
10.37
10.16
10.88
11.95
12.29
Book Value per Share
5.78
8.97
8.6
8.86
9.21
10.04
10.49
11.29
10.87
12.16
13.35
14.59
17.22
16.94
18.04
18.37
18.78
Tangible Book Value per Share
1,993
2,421
2,689
2,689
2,689
2,689
2,689
2,689
2,833
2,834
2,846
2,846
3,489
3,694
3,701
3,717
3,731
Basic Weighted Avg Shares
38,722
54,900
68,078
78,223
92,399
105,517
120,765
130,847
159,084
186,566
191,909
215,824
231,981
260,295
275,251
283,580
214,599
Sales/Revenue/Turnover
5.24
4.43
3.92
3.71
3.67
3.75
3.53
3.8
3.92
4.25
4.24
3.67
3.79
3.67
3.52
3.27
3.48
Operating Margin (%)
398
479
537
550
585
673
746
840
1,169
1,885
2,138
2,140
2,222
2,187
2,419
2,862
- -
Depreciation Expense
1,456
2,042
2,053
2,214
2,591
2,877
3,196
3,521
3,881
4,081
4,496
5,093
5,617
3,768
4,553
5,725
5,121
Net Income, GAAP
18.21
19.41
20.31
19.48
21.26
19.36
17.45
22.04
16.6
22.86
21.88
22.95
20.62
26.76
26.81
28.98
28.07
Effective Tax Rate (%)
3.76
3.72
3.02
2.83
2.8
2.73
2.65
2.69
2.44
2.19
2.34
2.36
2.42
1.45
1.65
2.02
2.39
Profit Margin (%)
5,072
15,140
16,704
16,812
16,656
16,159
19,154
19,010
24,568
23,484
19,430
24,670
38,822
40,062
45,785
45,266
46,333
Working Capital
66
52
41
125
105
93
2,836
2,959
9,600
10,290
2,685
8,592
7,561
7,336
9,728
5,385
4,720
LT Debt
12,828
25,981
27,701
29,001
31,099
33,808
36,834
39,676
46,433
49,386
54,741
59,066
78,002
80,326
83,742
89,787
91,468
Total Equity
10.43
7.95
6.68
6.97
7.28
7.67
7.55
7.38
7.78
7.52
7.34
9.71
9.07
5.81
5.53
4.85
3.76
Return on Invested Capital (%)
11.06
13.29
11.92
11.56
12.04
10.82
9.7
9.62
8.36
6.87
6.59
7.16
7.04
4.15
4.68
5.36
4.71
Return on Capital (%)
35.26
30.5
23.74
21.79
21.95
21.04
20.31
19.51
18.73
17.37
17.06
17.17
16.61
10.22
11.71
13.52
11.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
46,901
48,871
LT Borrowings
- -
4,236
3,257
LT Finance Leases
- -
1,149
1,463
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
3,708
3,708
Market Capitalization
41,593
37,866
37,919

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
180,464
182,841
Cash, Cash Equivalents & STI
- -
43,083
41,117
Accounts Receivable, Net
- -
82,306
91,150
Inventories
- -
45,359
41,682
Total Current Liabilities
- -
135,198
136,509
Payables & Accruals
- -
- -
- -
ST Debt
- -
46,901
48,871
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
10.88%
7.22%
Free Cash Flow
-13.17%
23.22%
11.73%
Net Income, GAAP
8.4%
7.44%
25.74%
Sales/Revenue/Turnover
10.54%
8.19%
3.03%
Total Cash Common Dividend
8.71%
4.63%
-22.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70,153
69,260
70,216
65,622
275,251
2025
70,763
70,830
- -
68,507
283,580
2026
75,262
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
- -
- -
- -
1.23
2025
0.36
- -
- -
- -
1.54
2026
0.38
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
- -
- -
- -
0.97
2025
0.11
- -
- -
- -
0.75
2026
0.18
- -
- -
- -
- -
Similar Companies
TGC Ventures International, Inc. (TGVN)
Rajnish Wellness Limited (RAJNISH.BO)
Medios AG (ILM1.DE)
Galenica AG (0ROG.L)
Sinopharm Group Co. Ltd. (SHTDY)
Evoq Remedies Ltd. (EVOQ.BO)
Business
Shanghai Pharmaceuticals Holding Co., Ltd. (2607.HK) engages in the research, development, manufacturing, distribution, and retail of pharmaceutical and healthcare products primarily in China and internationally. Founded in 1994 and headquartered in Shanghai, the company operates through four main segments—Production, Distribution, Retail, and Others—focusing on therapeutic areas including immunology and anti-cancer, cardiovascular, anti-infection, nervous system and mental disorders, digestive and metabolic systems, musculoskeletal, respiratory, and oncology; its core products encompass chemical and biological drugs, traditional Chinese medicines, healthcare products, and medical devices, produced in over 20 dosage forms across manufacturing bases in eight provinces, with key offerings for conditions such as diarrhoea, jaundice, fever, iron deficiency anaemia, pancreatitis, coronary heart disease, lupus erythematosus, leprosy, and acute myocardial infarction. The Production segment handles R&D, manufacturing, and sales of these pharmaceuticals; Distribution provides logistics, warehousing, supply chain solutions, and services to manufacturers, hospitals, and pharmacies; Retail manages a network of chained drugstores across 16 provinces with online-offline integration; and Others includes emerging healthcare services like hospital management and outpatient care, devices, and big health products. Recent developments include new product approvals such as ursodeoxycholic acid capsules, omeprazole, and sodium drugs by subsidiary Changzhou Pharmaceutical Factory; strategic partnerships with Astellas, Akeso, and others for innovative drug commercialization, driving 23.2% year-on-year sales growth to RMB12.5 billion; expansion of CSO business with 9.89% revenue increase; 6.9% growth in devices and big health to RMB10.9 billion; launch of the Production and Education Integration Center and Shanghai Key Laboratory of Innovative Target Antibody Coupled Drugs; a 10% equity acquisition in a finance company; ongoing connected transactions with Yunnan Baiyao Group and property leasing with Shanghai Pharma Group; and proposed governance changes abolishing the Supervisory Board for an audit committee per updated regulations. As China's largest pharmaceutical distributor for imported drugs and a leader in the A+H dual listing, Shanghai Pharmaceuticals maintains a robust presence with over 3,000 sales channels, significant R&D investment of around RMB3 billion annually, and operations emphasizing innovation, supply chain efficiency, and market expansion.